TherapeuticsMD (TXMD) Tops Q3 EPS by 5c

TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.16), $0.05 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $3.5 million versus the consensus estimate of $4.43 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Morgan Stanley upgrades CDW on stronger AI-driven server demand
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance